Study Details
Full Title
A 52-week, multicenter, randomized, double-blind, placebocontrolled,
parallel-group, flexible-adaptive, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease (LIBRA)
parallel-group, flexible-adaptive, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease (LIBRA)
Principal Investigator
Nirmish
Shah
Protocol Number
PRO00119562
NCT ID
NCT06975865
Phase
III
Enrollment Status
Open to Enrollment